2025
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDasatinibFemaleFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNiacinamidePhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisonePyrazolesConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemia
2024
HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML. Leukemia & Lymphoma 2024, 66: 270-278. PMID: 39397429, DOI: 10.1080/10428194.2024.2411436.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicDNA MethylationFemaleHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMiddle AgedMutationPrognosisRetrospective StudiesSulfonamidesSurvival RateTreatment OutcomeConceptsAcute myeloid leukemiaTreatment modificationHypomethylating agentsResponse rateAssociated with lower response ratesMedian overall survivalIDH-mutated acute myeloid leukemiaLong-term toxicityCR/CRi rateSignificant neutropeniaFebrile neutropeniaInduction chemotherapyOverall survivalMyeloid leukemiaLow response rateSurvival rateAffect survivalNeutropeniaVenetoclaxSurvivalED visitsPatientsR/RMonthsReal-world settingsMolecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, Neuberg D, DeAngelo D, Stone R, Lindsley R. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 2024, 38: 1494-1500. PMID: 38538860, PMCID: PMC11216982, DOI: 10.1038/s41375-024-02230-w.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicDNA MethylationFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMutationPrognosisRemission InductionSulfonamidesSurvival RateTumor Suppressor Protein p53Young AdultConceptsAcute myeloid leukemiaDiagnosed AML patientsHypomethylating agentsAML patientsTP53-mutated acute myeloid leukemiaPatients treated with intensive chemotherapyAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationComposite complete remissionStem cell transplantationGroup of patientsMolecular ontogenyMedian OSOS benefitComplete remissionIntensive chemotherapyCell transplantationClinicopathological variablesMyeloid leukemiaClinical benefitClinical impactSplicing mutationPatientsSecondary groupVenetoclax
2023
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review
Sherban A, Fredman D, Shimony S, Yeshurun M, Raanani P, Stahl M, Gafter-Gvili A, Wolach O. Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review. Leukemia Research 2023, 133: 107368. PMID: 37598660, DOI: 10.1016/j.leukres.2023.107368.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCytarabineHumansIdarubicinLeukemia, Myeloid, AcuteConceptsAcute myeloid leukemiaIntensive chemotherapyEfficacy outcomesHigh-risk acute myeloid leukemiaResponse to treatmentFLAG-IdaRelapsed/refractory patientsMyeloid leukemiaTreated patientsVenetoclaxSafety outcomesSystematic reviewEfficacyInfection ratePatientsTreatmentOutcomesChemotherapyLeukemiaSafetyTherapyReviewInfectionA systematic review
2022
Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia
Przespolewski A, Goldberg A, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, Waksal J, Ball B, Famulare C, Stahl M, Baron J, Griffiths E, Thompson J, Sweet K, Wang E. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia. Blood 2022, 141: 1489-1493. PMID: 36493344, DOI: 10.1182/blood.2022016678.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsCytarabineDaunorubicinHumansLeukemia, Myeloid, AcuteMiddle AgedNeoplasms, Second Primary
2021
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
Shimony S, Stone R, Stahl M. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Current Opinion In Hematology 2021, 29: 63-73. PMID: 34966123, DOI: 10.1097/moh.0000000000000698.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCytarabineHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSulfonamidesConceptsAcute myeloid leukemiaVenetoclax-based combination therapiesCombination therapyMyelodysplastic syndromeMyeloid leukemiaNewly diagnosed acute myeloid leukemiaAcute myeloid leukemia patientsVenetoclax combination therapyDeep molecular responseIncomplete count recoveryLow dose cytarabineBcl-2 inhibitorsHigh-risk populationRelapsed myelodysplastic syndromeProlonged cytopeniasDose cytarabineCount recoveryHypomethylating agentsRemission rateTargeted therapyTherapyBcl-2Therapeutic possibilitiesLong-term effectsPatient outcomesMulticenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms
King A, Weis T, Derkach A, Ball S, Pandey M, Mauro M, Goldberg A, Stahl M, Famulare C, Tallman M, Wang E, Kuykendall A, Rampal R. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal Of Hematology 2021, 97: e7-e10. PMID: 34674293, DOI: 10.1002/ajh.26381.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicFemaleHumansMaleMiddle AgedMyeloproliferative DisordersRetrospective StudiesSulfonamidesTreatment OutcomeClinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Horvat T, Abdel-Wahab O, Levine R, Viny A, Stein E, Cai S, Roshal M, Tallman M, Goldberg A. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances 2021, 5: 1552-1564. PMID: 33687434, PMCID: PMC7948282, DOI: 10.1182/bloodadvances.2020003734.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicDecitabineHumansLeukemia, Myeloid, AcuteNucleophosminRetrospective StudiesSulfonamidesConceptsLow-dose cytarabineAcute myeloid leukemiaMolecular predictors of responseRR-AMLPredictors of responseHigh response rateVenetoclax therapyOverall survivalResponse rateMolecular predictorsAssociated with higher response ratesMorphologic leukemia-free stateAllogeneic stem cell transplantationAssociated with worse OSRefractory acute myeloid leukemiaRelapsed/refractory acute myeloid leukemiaEvaluate novel agentsIncomplete hematologic recoveryMedian overall survivalVenetoclax combination therapyStem cell transplantationOverall response rateAcquisition of novel mutationsVenetoclax combinationsAdverse cytogenetics
2020
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal Of Hematology 2020, 113: 92-99. PMID: 32951163, DOI: 10.1007/s12185-020-02994-8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCell Cycle ProteinsDecitabineDose-Response Relationship, DrugFebrile NeutropeniaFeeding and Eating DisordersFemaleGene ExpressionHumansLeukemia, Myeloid, AcuteMaleMolecular Targeted TherapyProtein Serine-Threonine KinasesProto-Oncogene ProteinsPteridinesTreatment OutcomeConceptsAcute myeloid leukemiaMyeloid leukemiaCommon treatment-emergent adverse eventsPhase 1 dose-escalation trialTreatment-emergent adverse eventsMTD of volasertibObjective response rateAdverse event profileDose-escalation trialPhase 1 trialAnti-leukemic activityPolo-like kinase 1Febrile neutropeniaEscalation trialAdverse eventsCell cycle kinase inhibitorsAML patientsEvent profilePoor prognosisResponse ratePatientsVolasertibDecitabineKinase inhibitorsNumerous cancersVenetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
Bewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM, Stahl M. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 2020, 105: 2659-2663. PMID: 33131256, PMCID: PMC7604631, DOI: 10.3324/haematol.2019.242826.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCytarabineHumansLeukemia, Myeloid, AcuteSulfonamides
2019
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all
Stahl M, Tallman M. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leukemia & Lymphoma 2019, 60: 3107-3115. PMID: 31842650, PMCID: PMC7479633, DOI: 10.1080/10428194.2019.1613540.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideDisease-Free SurvivalHemorrhageHumansIncidenceLeukemia, Promyelocytic, AcuteMortalityNeoplasm Recurrence, LocalPractice Guidelines as TopicRandomized Controlled Trials as TopicRemission InductionStandard of CareTime FactorsTretinoinConceptsAcute promyelocytic leukemiaApplication of all-trans retinoic acidArsenic trioxideHigher early death rateHigh-risk acute promyelocytic leukemiaOutcome of high-riskRelapsed APLPromyelocytic leukemiaEarly death rateRelapsed APL patientsTreatment of acute promyelocytic leukemiaAll-trans retinoic acidAPL patientsCare of patientsEarly deathHigh riskPatientsLeukemiaRetinoic acidDeath rate
2016
Selecting initial treatment of acute myeloid leukaemia in older adults
Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Reviews 2016, 31: 43-62. PMID: 27745715, DOI: 10.1016/j.blre.2016.09.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsClinical Decision-MakingClinical Trials as TopicCombined Modality TherapyDisease ManagementHumansIncidenceLeukemia, Myeloid, AcutePrognosisTreatment OutcomeConceptsAcute myeloid leukemiaTreatment-related mortalityInduction chemotherapyComplete remissionInitial treatmentMyeloid leukemiaNovel agentsOlder adultsMedian overall survivalGroup of patientsPhase III developmentDisease-related characteristicsMechanism of actionCPX-351Overall survivalLow-intensity treatmentClinical trialsTreatment outcomesPatientsRemissionChemotherapyLeukemiaMortalityTreatmentAdultsSingle agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia
Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAged, 80 and overAntibodies, BispecificAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone MarrowBreast NeoplasmsCarcinoma, Transitional CellCytarabineFemaleHumansLymphoma, B-CellMercaptopurineMethotrexateNeoplasms, Second PrimaryPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrednisoneRemission InductionSalvage TherapyUrinary Bladder NeoplasmsVincristine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply